U.S. National Phase of PCT/GB95/01253

- 28. The modified toxin of Claim 1, wherein said drug or bioactive molecule is a polypeptide having an enzymatic activity.
- 29. The modified toxin of Claim 28, wherein the enzymatic activity of said polypeptide is different from an enzymatic activity of a light chain of said active Clostridial neurotoxin.
- 30. The modified toxin of Claim 28, wherein said enzymatic activity is a proteolytic cleavage activity characteristic of a Clostridial neurotoxin light chain.
- 31. The modified toxin of Claim 29, wherein said Clostridial neurotoxin light chain is Tetanus toxin light chain.
- 32. The modified toxin of Claim 1, wherein said drug or bioactive molecule is a polynucleotide.

REMARKS

New Claims 26-32 have been added to more precisely claim the invention. Support for the new claims can be found in the specification at the fourth paragraph on page 9; in the first row of the table on page 13. As a result of this supplemental preliminary amendment, Claims 1-4, 7-8, 15-25 and 26-32 are presented for examination. No new matter is being added herewith. Should there be any questions concerning this application, the Examiner is invited to contact the undersigned attorney at the telephone number appearing below.

Respectfully submitted,

KNOBBE, MARTENS, OLSON & BEAR, LLP

Dated: 29 April 1997

Daniel E. Altman

Registration No. 34,115

620 Newport Center Drive

Sixteenth Floor

Newport Beach, CA 92660

(714) 760-0404

MJG-2051:kc 042997